ZA200307955B - Treatment of ADHD. - Google Patents

Treatment of ADHD. Download PDF

Info

Publication number
ZA200307955B
ZA200307955B ZA200307955A ZA200307955A ZA200307955B ZA 200307955 B ZA200307955 B ZA 200307955B ZA 200307955 A ZA200307955 A ZA 200307955A ZA 200307955 A ZA200307955 A ZA 200307955A ZA 200307955 B ZA200307955 B ZA 200307955B
Authority
ZA
South Africa
Prior art keywords
adhd
tetrahydropyridin
indol
indole
dihydro
Prior art date
Application number
ZA200307955A
Other languages
English (en)
Inventor
Klaus Peter Hertel
Jom Arnt
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ZA200307955B publication Critical patent/ZA200307955B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Recrystallisation Techniques (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
ZA200307955A 2001-05-09 2003-10-13 Treatment of ADHD. ZA200307955B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100732 2001-05-09

Publications (1)

Publication Number Publication Date
ZA200307955B true ZA200307955B (en) 2004-10-13

Family

ID=8160484

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200307955A ZA200307955B (en) 2001-05-09 2003-10-13 Treatment of ADHD.

Country Status (23)

Country Link
US (1) US7294638B2 (bg)
EP (1) EP1387682A1 (bg)
JP (1) JP2004528361A (bg)
KR (1) KR20040007544A (bg)
CN (1) CN1507351A (bg)
AR (1) AR033287A1 (bg)
BG (1) BG108400A (bg)
BR (1) BR0209443A (bg)
CA (1) CA2446652A1 (bg)
CO (1) CO5540378A2 (bg)
CZ (1) CZ20033197A3 (bg)
EA (1) EA200301221A1 (bg)
HR (1) HRP20030852A2 (bg)
HU (1) HUP0400075A2 (bg)
IL (1) IL158413A0 (bg)
IS (1) IS6992A (bg)
MX (1) MXPA03010136A (bg)
NO (1) NO20034972L (bg)
NZ (1) NZ528896A (bg)
PL (1) PL367778A1 (bg)
SK (1) SK15002003A3 (bg)
WO (1) WO2002089797A1 (bg)
ZA (1) ZA200307955B (bg)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003236207A1 (en) * 2002-05-31 2003-12-19 H. Lundbeck A/S The hydrochloride of (s)-(+)-3-(1-(2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-6-chloro-1h-indole
EP1812390A2 (en) * 2004-10-22 2007-08-01 Mark Froimowitz Methylphenidate analogs and methods of use thereof
WO2009136410A2 (en) 2008-04-19 2009-11-12 Nisarga Biotech Pvt. Ltd. Herbal composition for reducing add/adhd and method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
WO2002046156A2 (en) * 2000-12-06 2002-06-13 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands

Also Published As

Publication number Publication date
HUP0400075A2 (hu) 2004-04-28
WO2002089797A1 (en) 2002-11-14
WO2002089797A8 (en) 2004-03-25
SK15002003A3 (sk) 2004-05-04
NO20034972D0 (no) 2003-11-07
EA200301221A1 (ru) 2004-04-29
EP1387682A1 (en) 2004-02-11
HRP20030852A2 (en) 2005-06-30
IS6992A (is) 2003-10-13
MXPA03010136A (es) 2004-03-10
BR0209443A (pt) 2004-08-03
US7294638B2 (en) 2007-11-13
NZ528896A (en) 2004-12-24
JP2004528361A (ja) 2004-09-16
US20040152737A1 (en) 2004-08-05
PL367778A1 (en) 2005-03-07
BG108400A (bg) 2004-11-30
CN1507351A (zh) 2004-06-23
CZ20033197A3 (en) 2004-06-16
IL158413A0 (en) 2004-05-12
NO20034972L (no) 2003-11-07
CA2446652A1 (en) 2002-11-14
KR20040007544A (ko) 2004-01-24
CO5540378A2 (es) 2005-07-29
AR033287A1 (es) 2003-12-10

Similar Documents

Publication Publication Date Title
CN1087937C (zh) 抑制阿尔茨海默症的药物
US6436938B1 (en) Combination treatment for depression
US6380199B1 (en) Use of 5HT6 antagonists
US20060241144A1 (en) Method for treating apathy syndrome
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
WO2015089111A1 (en) Novel methods
US7294638B2 (en) Treatment of ADHD
JP2018203774A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
AU2002254875A1 (en) Treatment of ADHD
JP2006523650A (ja) うつ病および/または不安の治療用のパロキセチンと4−(s)−(4−アセチル−ピペラジン−1−イル)−2−(r)−(4−フルオロ−2−メチル−フェニル)−ピペリジン−1−カルボン酸[1−(r)−(3,5−ビス−トリフルオロメチル−フェニル)−エチル]メチルアミドとの組合せ
MXPA05000791A (es) Compuestos de 1-fenil-2-dimetilaminometil ciclohexano para la terapia de sintomas depresivos, dolor e incontinencia.
EP1942891B1 (en) Novel combination of drugs as antidepressant
AU643431B2 (en) Use of chlormethiazole in the prevention and/or treatment of neurodegeneration
Chang et al. Catatonia associated with coadministration of tramadol and meperidine
KR20010099648A (ko) 신규 조성물
US20070197592A1 (en) Use of Paliperidone for the Treatment of Substance Abuse
WO2005067909A1 (en) Combination therapy with mecamylamine for the treatment of mood disorders
AU4279599A (en) Use of an nk-1 receptor antagonist for treating cognitive disorders
WO2024059631A1 (en) R-trihexyphenidyl for treatment of movement disorders
Scates et al. Focus on citalopram: A selective serotonin reuptake inhibitor for the treatment of depression
US20090203738A1 (en) Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia
CN1466587A (zh) 含有2-芳基-8-氧代二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
WO1999064006A1 (en) Use of a nk-1 receptor antagonist for treating psychiatric disorders
Hanna Comments on guest editorial," Chronic fatigue syndrome, mast cells, and tricyclic antidepressants"
ZA200101910B (en) Treatment of depression.